In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria

R. Leon-Barua, R. Tello, M. Del Carmen Morante, M. Alvarez, Robert H Gilman, W. M. Spira

Research output: Contribution to journalArticle

Abstract

Three bismuth compounds (tripotassium dicitrate bismuthate, bismuth subsalicylate, and bismuth subnitrate) were tested in vitro and in vivo for their effect on fermentation by colonic bacteria. The studies in vitro were done with use of a technique designed to determine the effect of each one of the bismuth compounds on the fermentation of several stool samples that had been mixed with lactose as additional fermentable substrate (fermentation of lactose-enriched stools, FLES). The three bismuth compounds reduced FLES significantly in 47 (81%) of 58 of the stool samples used to test their effect. Bismuth subsalicylate, which reduced FLES in 10 of 10 stool samples, showed the greatest reduction (mean reduction, 74%; P <.0001). The in vivo studies, done in six flatulent patients, showed significant reduction (P <.01) of colonic fermentation of ingested raffinose by oral bismuth subnitrate given for 8 days.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume12
Issue numberSUPPL. 1
StatePublished - 1990

Fingerprint

Bismuth
Fermentation
Lactose
Bacteria
Raffinose
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Leon-Barua, R., Tello, R., Del Carmen Morante, M., Alvarez, M., Gilman, R. H., & Spira, W. M. (1990). In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria. Reviews of Infectious Diseases, 12(SUPPL. 1).

In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria. / Leon-Barua, R.; Tello, R.; Del Carmen Morante, M.; Alvarez, M.; Gilman, Robert H; Spira, W. M.

In: Reviews of Infectious Diseases, Vol. 12, No. SUPPL. 1, 1990.

Research output: Contribution to journalArticle

Leon-Barua, R, Tello, R, Del Carmen Morante, M, Alvarez, M, Gilman, RH & Spira, WM 1990, 'In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria', Reviews of Infectious Diseases, vol. 12, no. SUPPL. 1.
Leon-Barua R, Tello R, Del Carmen Morante M, Alvarez M, Gilman RH, Spira WM. In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria. Reviews of Infectious Diseases. 1990;12(SUPPL. 1).
Leon-Barua, R. ; Tello, R. ; Del Carmen Morante, M. ; Alvarez, M. ; Gilman, Robert H ; Spira, W. M. / In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria. In: Reviews of Infectious Diseases. 1990 ; Vol. 12, No. SUPPL. 1.
@article{ea29c35e8ab444f492391a2d6942f815,
title = "In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria",
abstract = "Three bismuth compounds (tripotassium dicitrate bismuthate, bismuth subsalicylate, and bismuth subnitrate) were tested in vitro and in vivo for their effect on fermentation by colonic bacteria. The studies in vitro were done with use of a technique designed to determine the effect of each one of the bismuth compounds on the fermentation of several stool samples that had been mixed with lactose as additional fermentable substrate (fermentation of lactose-enriched stools, FLES). The three bismuth compounds reduced FLES significantly in 47 (81{\%}) of 58 of the stool samples used to test their effect. Bismuth subsalicylate, which reduced FLES in 10 of 10 stool samples, showed the greatest reduction (mean reduction, 74{\%}; P <.0001). The in vivo studies, done in six flatulent patients, showed significant reduction (P <.01) of colonic fermentation of ingested raffinose by oral bismuth subnitrate given for 8 days.",
author = "R. Leon-Barua and R. Tello and {Del Carmen Morante}, M. and M. Alvarez and Gilman, {Robert H} and Spira, {W. M.}",
year = "1990",
language = "English (US)",
volume = "12",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - In vitro and in vivo effects of three bismuth compounds on fermentation by colonic bacteria

AU - Leon-Barua, R.

AU - Tello, R.

AU - Del Carmen Morante, M.

AU - Alvarez, M.

AU - Gilman, Robert H

AU - Spira, W. M.

PY - 1990

Y1 - 1990

N2 - Three bismuth compounds (tripotassium dicitrate bismuthate, bismuth subsalicylate, and bismuth subnitrate) were tested in vitro and in vivo for their effect on fermentation by colonic bacteria. The studies in vitro were done with use of a technique designed to determine the effect of each one of the bismuth compounds on the fermentation of several stool samples that had been mixed with lactose as additional fermentable substrate (fermentation of lactose-enriched stools, FLES). The three bismuth compounds reduced FLES significantly in 47 (81%) of 58 of the stool samples used to test their effect. Bismuth subsalicylate, which reduced FLES in 10 of 10 stool samples, showed the greatest reduction (mean reduction, 74%; P <.0001). The in vivo studies, done in six flatulent patients, showed significant reduction (P <.01) of colonic fermentation of ingested raffinose by oral bismuth subnitrate given for 8 days.

AB - Three bismuth compounds (tripotassium dicitrate bismuthate, bismuth subsalicylate, and bismuth subnitrate) were tested in vitro and in vivo for their effect on fermentation by colonic bacteria. The studies in vitro were done with use of a technique designed to determine the effect of each one of the bismuth compounds on the fermentation of several stool samples that had been mixed with lactose as additional fermentable substrate (fermentation of lactose-enriched stools, FLES). The three bismuth compounds reduced FLES significantly in 47 (81%) of 58 of the stool samples used to test their effect. Bismuth subsalicylate, which reduced FLES in 10 of 10 stool samples, showed the greatest reduction (mean reduction, 74%; P <.0001). The in vivo studies, done in six flatulent patients, showed significant reduction (P <.01) of colonic fermentation of ingested raffinose by oral bismuth subnitrate given for 8 days.

UR - http://www.scopus.com/inward/record.url?scp=0025129023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025129023&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -